Corindus Vascular Robotics has announced that the second generation of its CorPath Vascular Robotics System was cleared by the FDA and is slated for commercialization early next year.

CorPath GRX includes upgrades that improve its precision and workflow while broadening the range of procedures that it can perform. The bedside unit has been completely redesigned and includes an extended reach arm and a touch screen display.

The new Active Guide Management feature allows the user to control the guide catheter and robotically maneuver the guide wire and balloon or stent catheter from the remote console. That allows the physician to adjust the position of the guide catheter during percutaneous coronary intervention (PCI) procedures.
"The new features of the next generation CorPath System, particularly the addition of active guide catheter management, will allow physicians to increase the complexity of procedures performed robotically,” Dr. J. Aaron Grantham, chief medical officer of Corindus, said in a statement.

According to the company, CorPath is the first and only device cleared by the FDA to robotically perform PCI and protect clinicians from radiation exposure in the cath lab. The CorPath GRX will be showcased at the Transcatheter Cardiovascular Therapeutics 2016 conference later this week.

Cardiology Homepage